We are live on ! Find out more
ARQT icon

Arcutis Biotherapeutics
ARQT

106 hedge funds and large institutions have $895M invested in Arcutis Biotherapeutics in 2022 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 31 increasing their positions, 29 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

547% more call options, than puts

Call options by funds: $2.88M | Put options by funds: $445K

175% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 8

14% more funds holding

Funds holding: 93 → 106 (+13)

3.7% more ownership

Funds ownership: 92.19% → 95.89% (+3.7%)

7% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 29

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

3% less capital invested

Capital invested by funds: $925M → $895M (-$29.1M)

Holders
106
Holders Change
+13
Holders Change %
+13.98%
% of All Funds
1.67%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
22
Increased
31
Reduced
29
Closed
8
Calls
$2.88M
Puts
$445K
Net Calls
+$2.44M
Net Calls Change
+$1.36M

Top Buyers

Rank Fund Capital Flow
1
LGM
Logos Global Management
California
+$21.1M
2
EC
EcoR1 Capital
California
+$15.1M
3
MB
MPM BioImpact
Massachusetts
+$4.37M
4
Ameriprise
Ameriprise
Minnesota
+$3.62M
5
GKIM
GW&K Investment Management
Massachusetts
+$3.59M

Top Sellers

Rank Fund Capital Flow
1
FM
Frazier Management
Washington
-$175M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$16M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$6.33M
4
Norges Bank
Norges Bank
Norway
-$3.46M
5
Citigroup
Citigroup
New York
-$1.84M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$3.87M +$42.5K +2,511 +1%
PVI
27
Pura Vida Investments
New York
$3.65M +$858K +50,700 +37%
N
28
Nuveen
North Carolina
$3.57M +$95.4K +5,641 +3%
Citadel Advisors
29
Citadel Advisors
Florida
$3.4M -$1.19M -70,215 -28%
Wells Fargo
30
Wells Fargo
California
$2.67M -$47.8K -2,827 -2%
TCM
31
Tekla Capital Management
Massachusetts
$2.54M – – –
Neuberger Berman Group
32
Neuberger Berman Group
New York
$2.49M +$121K +7,179 +6%
Millennium Management
33
Millennium Management
New York
$1.93M +$1.69M +100,126 New
Morgan Stanley
34
Morgan Stanley
New York
$1.88M +$752K +44,433 +84%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$1.86M -$19.9K -1,177 -1%
HSBC Holdings
36
HSBC Holdings
United Kingdom
$1.77M +$972K +57,465 +166%
HWAM
37
Hennion & Walsh Asset Management
New Jersey
$1.68M +$373K +22,021 +34%
Walleye Capital
38
Walleye Capital
New York
$1.46M -$133K -7,867 -9%
1CM
39
1492 Capital Management
Wisconsin
$1.45M +$1.27M +75,192 New
Goldman Sachs
40
Goldman Sachs
New York
$1.21M +$243K +14,339 +30%
Norges Bank
41
Norges Bank
Norway
$1.18M -$3.46M -204,277 -77%
Swiss National Bank
42
Swiss National Bank
Switzerland
$1.15M +$72.7K +4,300 +8%
Rafferty Asset Management
43
Rafferty Asset Management
New York
$1.1M +$6.92K +409 +0.7%
UBS Group
44
UBS Group
Switzerland
$1.05M -$6.11K -361 -0.7%
HLA
45
Hamilton Lane Advisors
Pennsylvania
$1.01M – – –
AA
46
ALPS Advisors
Colorado
$997K -$109K -6,420 -11%
Barclays
47
Barclays
United Kingdom
$730K +$642K +37,938 New
RhumbLine Advisers
48
RhumbLine Advisers
Massachusetts
$681K -$4.43K -262 -0.7%
California State Teachers Retirement System (CalSTRS)
49
California State Teachers Retirement System (CalSTRS)
California
$646K -$46.3K -2,739 -8%
UBS AM
50
UBS AM
Illinois
$577K – – –
1
2
3 4 5

ARQT Hedge Fund Activity: Q1 2022 in Review

106 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q1 2022, worth a combined $895M — down 3.1% from $925M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new ARQT positions and 8 closed out — a net gain of 14 holders — while 31 added to existing stakes and 29 trimmed.

The largest buyer was Logos Global Management, adding an estimated $21.1M. The largest seller was Frazier Management, exiting entirely with an estimated $175M sold.

  • 106 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q1 2022, up from 93 in Q4 2021.
  • Funds reported $895M of Arcutis Biotherapeutics stock for Q1 2022, down 3.1% quarter-over-quarter.
  • 22 funds opened new Arcutis Biotherapeutics positions in Q1 2022 and 8 closed out, a net change of +14 holders.
  • The largest Arcutis Biotherapeutics buyer in Q1 2022 was Logos Global Management, an estimated $21.1M added.
  • The largest Arcutis Biotherapeutics seller in Q1 2022 was Frazier Management, an estimated $175M sold.

Based on aggregated 13F filings for Q1 2022.